JP2017538773A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538773A5 JP2017538773A5 JP2017533540A JP2017533540A JP2017538773A5 JP 2017538773 A5 JP2017538773 A5 JP 2017538773A5 JP 2017533540 A JP2017533540 A JP 2017533540A JP 2017533540 A JP2017533540 A JP 2017533540A JP 2017538773 A5 JP2017538773 A5 JP 2017538773A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- heteroaryl
- aryl
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 23
- -1 substituted Chemical class 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 21
- 150000002431 hydrogen Chemical class 0.000 claims 21
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 14
- 125000003107 substituted aryl group Chemical group 0.000 claims 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000002947 alkylene group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 102100038495 Bile acid receptor Human genes 0.000 claims 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 238000010276 construction Methods 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000007870 cholestasis Effects 0.000 claims 1
- 231100000359 cholestasis Toxicity 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 0 C*(*)c1nnc(*)[o]1 Chemical compound C*(*)c1nnc(*)[o]1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095646P | 2014-12-22 | 2014-12-22 | |
| US62/095,646 | 2014-12-22 | ||
| PCT/IB2015/002549 WO2016103037A1 (en) | 2014-12-22 | 2015-12-21 | Fused bicyclic compounds for the treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020167254A Division JP7089566B2 (ja) | 2014-12-22 | 2020-10-01 | 疾患の処置のための縮合二環式化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017538773A JP2017538773A (ja) | 2017-12-28 |
| JP2017538773A5 true JP2017538773A5 (enExample) | 2019-02-07 |
Family
ID=55300724
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533540A Pending JP2017538773A (ja) | 2014-12-22 | 2015-12-21 | 疾患の処置のための縮合二環式化合物 |
| JP2020167254A Active JP7089566B2 (ja) | 2014-12-22 | 2020-10-01 | 疾患の処置のための縮合二環式化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020167254A Active JP7089566B2 (ja) | 2014-12-22 | 2020-10-01 | 疾患の処置のための縮合二環式化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10167294B2 (enExample) |
| EP (1) | EP3237419B1 (enExample) |
| JP (2) | JP2017538773A (enExample) |
| KR (1) | KR20170117030A (enExample) |
| CN (1) | CN107438612A (enExample) |
| AU (2) | AU2015370588B2 (enExample) |
| BR (1) | BR112017013568A2 (enExample) |
| CA (1) | CA2971755A1 (enExample) |
| CL (1) | CL2017001661A1 (enExample) |
| CO (1) | CO2017007121A2 (enExample) |
| IL (1) | IL252849B (enExample) |
| MX (1) | MX369623B (enExample) |
| RU (2) | RU2741387C2 (enExample) |
| SG (1) | SG11201704770YA (enExample) |
| WO (1) | WO2016103037A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2741387C2 (ru) * | 2014-12-22 | 2021-01-25 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения для лечения заболевания |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| JP6843061B2 (ja) * | 2015-03-26 | 2021-03-17 | アカーナ・セラピューティクス・リミテッドＡｋａｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｔｄ． | 疾患治療のための縮合二環化合物 |
| TW201808283A (zh) * | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| CN110128432B (zh) * | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| WO2021014349A1 (en) | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising fxr agonists |
| TW202114672A (zh) | 2019-07-23 | 2021-04-16 | 瑞士商諾華公司 | 使用fxr促效劑的肝臟疾病之組合治療 |
| MX2022002636A (es) | 2019-09-03 | 2022-03-25 | Novartis Ag | Tratamiento de la enfermedad o trastorno hepatico que comprende los antagonistas del receptor de actrii. |
| US20220347190A1 (en) | 2019-09-19 | 2022-11-03 | Novartis Ag | Treatment comprising fxr agonists |
| JP2022550312A (ja) | 2019-09-30 | 2022-12-01 | ノバルティス アーゲー | Ｆｘｒアゴニストの使用を含む処置 |
| IL293894A (en) | 2019-12-20 | 2022-08-01 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
| CN116710450A (zh) | 2020-12-22 | 2023-09-05 | 诺华股份有限公司 | 用于治疗与cGAS相关的病症的吡咯并[3,2-b]吡啶衍生物 |
| AU2021404953A1 (en) | 2020-12-22 | 2023-06-22 | Novartis Ag | Indole derivatives useful in treating conditions associated with cgas |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8466143B2 (en) * | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
| JP5420908B2 (ja) * | 2005-12-15 | 2014-02-19 | エグゼリクシス， インコーポレイテッド | 医薬的薬剤としてのアゼピノインドール誘導体 |
| RU2741387C2 (ru) * | 2014-12-22 | 2021-01-25 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения для лечения заболевания |
-
2015
- 2015-12-21 RU RU2017126128A patent/RU2741387C2/ru active
- 2015-12-21 BR BR112017013568A patent/BR112017013568A2/pt not_active Application Discontinuation
- 2015-12-21 EP EP15831230.6A patent/EP3237419B1/en active Active
- 2015-12-21 KR KR1020177020205A patent/KR20170117030A/ko not_active Abandoned
- 2015-12-21 RU RU2021100040A patent/RU2021100040A/ru not_active Application Discontinuation
- 2015-12-21 CA CA2971755A patent/CA2971755A1/en active Pending
- 2015-12-21 CN CN201580076617.4A patent/CN107438612A/zh active Pending
- 2015-12-21 SG SG11201704770YA patent/SG11201704770YA/en unknown
- 2015-12-21 WO PCT/IB2015/002549 patent/WO2016103037A1/en not_active Ceased
- 2015-12-21 MX MX2017008456A patent/MX369623B/es active IP Right Grant
- 2015-12-21 JP JP2017533540A patent/JP2017538773A/ja active Pending
- 2015-12-21 AU AU2015370588A patent/AU2015370588B2/en not_active Ceased
-
2017
- 2017-06-12 IL IL252849A patent/IL252849B/en unknown
- 2017-06-22 CL CL2017001661A patent/CL2017001661A1/es unknown
- 2017-06-22 US US15/630,189 patent/US10167294B2/en active Active
- 2017-07-17 CO CONC2017/0007121A patent/CO2017007121A2/es unknown
-
2018
- 2018-12-31 US US16/237,017 patent/US10793577B2/en active Active
-
2020
- 2020-09-17 US US17/024,095 patent/US20210139490A1/en not_active Abandoned
- 2020-10-01 JP JP2020167254A patent/JP7089566B2/ja active Active
- 2020-10-13 AU AU2020256336A patent/AU2020256336A1/en not_active Abandoned
-
2023
- 2023-05-02 US US18/311,171 patent/US20240025914A1/en not_active Abandoned
-
2024
- 2024-10-24 US US18/925,911 patent/US20250206753A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538773A5 (enExample) | ||
| RU2017121588A (ru) | Конденсированные бициклические соединения для лечения заболевания | |
| RU2021100040A (ru) | Конденсированные бициклические соединения для лечения заболевания | |
| JP2016506960A5 (enExample) | ||
| JP2016503799A5 (enExample) | ||
| JP2013525458A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2016512520A5 (enExample) | ||
| JP2014504646A5 (enExample) | ||
| JP2017535614A5 (enExample) | ||
| JP2009533410A5 (enExample) | ||
| JP2011513410A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2010524932A5 (enExample) | ||
| JP2015520140A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2016508505A5 (enExample) | ||
| RU2014125230A (ru) | Пиридонамиды и их аналоги, демонстрирующие противораковую и антипролиферативную активность | |
| JP2017526677A5 (enExample) | ||
| JP2016505614A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| JP2013544860A5 (enExample) | ||
| JP2017501237A5 (enExample) | ||
| JP2014510147A5 (enExample) |